Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
about
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomasConcordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesionsIntratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cellsGene therapy for carcinoma of the breast.Using antibodies in tumour immunotherapy.Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab.Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor.Monoclonal antibody therapy of ovarian cancer.Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.Role of monoclonal antibodies in tumor-specific immunity.Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer.Therapeutic antibodies against cancer stem cells: a promising approach.Spatial separation of the processing and MHC class I loading compartments for cross-presentation of the tumor-associated antigen HER2/neu by human dendritic cells.Silencing of ErbB3/ErbB2 signaling by immunoglobulin-like Necl-2.Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study.Identification of novel nuclear localization signal within the ErbB-2 protein.Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections.
P2860
Q24813451-16517248-9C3F-4D57-9287-A419CC64E49CQ30909247-ED8F1F4E-DCC7-4AF0-934C-2A743843E994Q33645792-DD059E48-7A6C-421E-9858-3302C3A60CADQ35609061-62CB8088-A04E-4AF6-8120-63081A302D8AQ35842612-75D85776-48F9-45F8-9EB6-C5098887AFA2Q35842690-4E20F851-1E9B-4027-99AC-7362F100F6B7Q35890518-82D594B8-5886-4800-A421-78BA2ADED549Q36066157-E03BA479-51BB-4A28-939E-16BD9AB3129EQ36648369-75D8D889-89C2-4F60-90F3-1E3DD9F94DD8Q36739762-B74EC1D2-FE8E-47F1-BB26-EF8F8D0893A5Q38452330-36096E9E-C7C8-4203-AF30-4856AC365D57Q38637435-98496CD2-5B7E-4DCA-88C4-0173DDF3BA71Q39014554-23DE1EC4-9B91-476B-88AF-B167BB59DCC0Q39832060-91B1803E-E2D3-45B7-99CB-9B990D97D6A5Q40499571-15A87F01-39C9-4759-BA0A-557F836AEDF4Q45267606-C961BADD-371F-43B9-A254-DD4FD3482493Q46620175-4007C3B6-C609-4E5E-B251-D9A022119211Q47316045-E0D2BBC9-D9A2-450A-9DA5-BFCC52B1E4F1
P2860
Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
@ast
Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
@en
Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
@nl
type
label
Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
@ast
Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
@en
Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
@nl
prefLabel
Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
@ast
Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
@en
Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
@nl
P356
P1476
Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
@en
P2093
P2888
P304
P356
10.1007/S002620100226
P50
P577
2001-11-24T00:00:00Z
P6179
1027419778